The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

doi:10.1016/S1470-2045(13)70240-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

The Lancet. Oncology - 1 Aug 2013

Sandhu Shahneen K, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Kreischer Nathan, Thway Khin, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Wenham Robert M

Abstract excerpt

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation. Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclinical tumour models with loss of BRCA and PTEN function. We investigated the safety, tolerability, maximum tolerated dose, pharmacokinetic and pharmacodynamic profiles, and preliminary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Indazoles

Share to Maximum Tolerated Dose

Share to Neoplasm Recurrence, Local

Share to Piperidines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Tissue Distribution

Source

Open in PubMed

Identifiers

PMID: 23810788
DOI: 10.1016/S1470-2045(13)70240-7

Genes

PTEN
BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.PMID 23810788Read ↗

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated SettingSemantic proximity Read ↗

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerSemantic proximity Read ↗

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancersSemantic proximity Read ↗

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.Semantic proximity Read ↗

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation CarriersSemantic proximity Read ↗

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic CancersSemantic proximity Read ↗

Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.Semantic proximity Read ↗

Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.Semantic proximity Read ↗

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.Semantic proximity Read ↗

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.Semantic proximity Read ↗

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Semantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.